Depression Drugs Market - Snapshot
Depression is an indication when one feels down in the dumps, miserable, unhappy, blue, or sad. It is natural for people to feel this way for a short duration of time, sometime in life. However, clinical depression is a condition when a person feels frustrated, angry, lost, or sad on a daily basis, for a long duration of time. In 2017, depression drugs were valued at approximately US$ 6,500 Mn and are anticipated to register a CAGR of over -2% from 2018 to 2026 to reach value of approximately over US$ 5000 Mn by 2026.
Increasing prevalence of major depression disorder drives the expansion of the market from 2018 to 2026. According to the National Institute of Mental Health, approximately 10.3 million adults in the U.S. had at least one major depressive episode with severe impairment in 2016. The number represented 4.3% of all adults in the U.S. Higher prevalence of depression was observed among female adults, which accounted for approximately 8.5% as against 4.8% among male adults. The highest prevalence of major depression disorder was observed among the people of 18 to 25 years of age, which accounted for 10.9% of all adults in the U.S affected by at least one major depressive episode with severe impairment in 2016. According to the American Psychiatric Association, approximately 14.8 million adults in the U.S. are affected by depression.
The global depression drugs market can be been classified on the basis of distribution channel, disease type, drug class, and region. Based on drug class, the market can be categorized into atypical antipsychotics, serotonin–norepinephrine reuptake inhibitor, selective serotonin reuptake inhibitor, central nervous system (CNS) stimulant, and others. Among these, the atypical antipsychotics segment leads the market and is expected to continue its dominance during the forecast period, followed by the Serotonin–Norepinephrine Reuptake Inhibitor segment. The significant market share of the atypical antipsychotics segment can be attributed to the launch of drugs in developed countries, such as the U.S. and Canada.
In terms of disease type, the depression drugs market can be been classified into major depressive disorder, schizophrenia and bipolar I disorder, selective serotonin reuptake inhibitor induced, and others. Major depression disorder accounted for highest market share in 2017 owing to high work stress all over the world.
Based on distribution channel, the depression drugs market can be bifurcated into online pharmacies, hospital pharmacies, and retail pharmacies. Among these, the retail pharmacies segment held the maximum share of the market in 2017. The segment is projected to dominate the market during the forecast period, which can be attributed to the increasing prevalence of depression disorders across the world and rising preference of patients to buy drugs from retail pharmacies. However, hospital pharmacies and retail pharmacies are anticipated to witness a decline in their market share during the forecast period owing to expiry of exclusivity of depression drugs.
Geographically, North America constituted the leading share of the global depression drugs market in 2017. North America being the home company of many key players of the global depression drugs market is likely responsible for the dominance of market share of the region. Europe accounted for the second leading share of the global depression drugs market in 2017, which can be ascribed to the increase in research and development activities on depression drugs in the region. The depression drugs market in Middle East & Africa is anticipated to grow at a significant rate during the forecast period. Increase in government initiatives in the health care sector in the developing countries of the region is projected to fuel the growth of the depression drugs market in the region. Initiatives by the local government to attain self-sufficiency in the manufacturing of depression drugs is likely to boost the depression drugs market in Asia Pacific and Latin America.
Major companies operating in the global depression drugs and profiled in the report include Otsuka Pharmaceutical Co., Ltd., Eli Lilly and Company, Pfizer Inc., AstraZeneca, Allergan USA, Inc., Novartis AG, GlaxoSmithKline, Takeda Pharmaceutical Company Ltd, Sebela Pharmaceutical Inc, and Johnson & Johnson. These players have adopted both inorganic and organic growth strategies to expand their drug offerings, strengthen their reach globally, garner market share, and increase their customer base.
Depression Drugs Market - Overview
This report analyzes the global depression drugs market in terms of its current and future scenario. Increase in prevalence of major depression disorders, rise in government initiatives in creating awareness about depression drugs, and growth in geriatric population across the world are expected to drive the depression drugs market during the forecast period.
The report on the global depression drugs market comprises an elaborate executive summary, including a market snapshot that provides information on various segments. It also provides information and data analysis of the global market with respect to its segments based on drug class, disease type, distribution channel, and geography. A detailed qualitative analysis of drivers and restraints, opportunities, and trends has been provided in the market overview section. Additionally, the section comprises product pipeline analysis to help understand the scope of the market. The section also provides market share analysis in terms of segments, geography and key players, thus presenting a thorough analysis of the overall competitive scenario in the global depression drugs market.
The global depression drugs market has been classified on the basis of drug class, disease type, distribution channel, and region. Based on drug class, the market has been categorized into atypical antipsychotics, serotonin–norepinephrine reuptake inhibitor, selective serotonin reuptake inhibitor, central nervous system (CNS) stimulant, and others. In terms of disease type, the market has been classified into major depressive disorder, schizophrenia and bipolar I disorder, selective serotonin reuptake inhibitor induced, and others. Based on distribution channel, the market has been segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
Geographically, the global depression drugs market has been categorized into five major regions and key countries in those regions: North America (U.S. and Canada), Europe (Germany, France, Italy, Spain, U.K., and Rest of Europe), Asia Pacific (China, Japan, India, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America) and Middle East & Africa (South Africa, Israel, GCC, and Rest of Middle East & Africa).
The report also profiles major players operating in the global depression drugs market based on various attributes, such as, company overview, financial overview, product portfolio, business strategies, SWOT analysis, and recent developments. Major players profiled in this report include Otsuka Pharmaceutical Co., Ltd., Eli Lilly and Company, Pfizer Inc., AstraZeneca, Allergan USA, Inc., Novartis AG, GlaxoSmithKline, and Takeda Pharmaceutical Company Ltd.
The global depression drugs market has been segmented as below:
Global Depression Drugs Market, by Drug Class
- Atypical antipsychotics
- Serotonin-norepinephrine reuptake inhibitors
- Selective serotonin reuptake inhibitors
- CNS stimulants
- Others (Benzodiazepines and miscellaneous antidepressants)
Global Depression Drugs Market, by Disease Type
- Major depressive disorders
- Schizophrenia and bipolar I disorder (manic depression)
- SSRI induced
- Others (attention deficit hyperactivity disorder and anxiety disorders)
Global Depression Drugs Market, by Distribution Channel
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
Global Depression Drugs Market, by Geography
- North America
- Rest of Europe
- Asia Pacific
- Australia & New Zealand
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of Middle East & Africa